Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients

Table 2 Sustained virological response rates n (%)

Group	Triple therapy		Dual therapy		P value
	n	SVR	n	SVR
All patients	88	75 (85.2)	122	52 (42.6)	< 0.001
Previous treatment response
Naïve/prior relapse	59	56 (94.9)
Prior NVR	27	17 (63.0)
Prior unknown response	2	2 (100)
IL28B SNP (rs8099917)
TT	49	48 (98.0)	73	45 (61.6)	< 0.001
TG/GG	39	27 (69.2)	31	1 (3.2)	< 0.001
Not determined, n	0	-	18	6 (33.3)	-
Stage of fibrosis
F0-2	52	48 (92.3)	76	43 (56.6)	< 0.001
F3-4	12	9 (75.0)	8	4 (50.0)	0.279
Not determined, n	24	18 (75.0)	38	5 (13.2)
Baseline HCV RNA level
≥ 6 log10 IU/mL	69	58 (84.1)	86	39 (45.3)	< 0.001
< 6 log10 IU/mL	19	17 (89.5)	36	23 (63.8)	0.032
Baseline platelet count
≥ 100 × 109/L	80	71 (88.8)	117	62 (53.0)	< 0.001
< 100 × 109/L	8	4 (50.0)	5	0 -	0.043
Baseline serum AFP level
< 10 ng/mL	68	63 (92.6)	96	49 (51.0)	< 0.001
≥ 10 ng/mL	20	12 (60.0)	26	3 (11.5)	< 0.001

Treatment response was analyzed by per-protocol analysis. AFP: Alpha-fetoprotein; Dual therapy: Pegylated-interferon-α and ribavirin; HCV: Hepatitis C virus; IL28B: Interleukin 28B; NVR: Non-virological response; SNP: Single-nucleotide polymorphism; Triple therapy: Telaprevir-based therapy combined with pegylated-interferon-α and ribavirin.